1. In forty non-smoking healthy subjects and seventy-two patients with left heart diseases measurements were made of the volume expired in the first second of a forced expiration (FEV,) and the total volume expired in a forced expiration (FVC) before and after inhalation of salbutamol. Before and after salbutamol the healthy subjects and patients also inhaled maximally an inspirate, the first part of which contained X e and, during controlled expiration, the radioactivity of the expirate was measured and plotted against its volume. The resulting curves were divided into phases of different slope by eye, the point at which phase 3 changed to phase 4 being nominated the closing volume.
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Summary
1. In forty non-smoking healthy subjects and seventy-two patients with left heart diseases measurements were made of the volume expired in the first second of a forced expiration (FEV,) and the total volume expired in a forced expiration (FVC) before and after inhalation of salbutamol. Before and after salbutamol the healthy subjects and patients also inhaled maximally an inspirate, the first part of which contained X e and, during controlled expiration, the radioactivity of the expirate was measured and plotted against its volume. The resulting curves were divided into phases of different slope by eye, the point at which phase 3 changed to phase 4 being nominated the closing volume.
2. In forty non-smoking healthy subjects inhalation of salbutamol was followed by significant increase in FEV, but FVC and closing volume did not change.
3. Change in posture from seated erect to supine in thirty of these healthy subjects was accompanied by significant reduction in FEV, and FVC and as closing volume was not significantly different in the two positions the ratio closing volume/vital capacity was increased with recumbency.
4. In seventy-two patients with left heart diseases without a history of cough or wheeze, FEVI, FVC, closing volume and the ratio closing volumelvital capacity were significantly different from values in the healthy subjects. There was no significant difference between non-smokers and ex-smokers amongst the patients. tion in closing volume and the ratio closing volume/ vital capacity followed inhalation of salbutamol in patients with heart diseases but the values remained significantly different from those recorded in the healthy subjects. 6. In twenty patients with heart diseases, FEV, and FVC were reduced by change in posture from seated erect to supine but the ratio closing volume/ iital capacity and the regression with age of this ratio were not significantly changed by change in position.
Significant increase in FEV,, FVC and reduc-
7. In patients with heart diseases the ratio closing volume/vital capacity was significantly correlated
Introduction
The effects which diseases of the left heart exert upon lung function are, in the main, a consequence of a raised pulmonary venous pressure. Severe pulmonary oedema may cause airflow obstruction of sufficient severity to merit the use of the term 'cardiac asthma', yet many patients with diseases affecting the left heart with clinical and haemodynamic signs of pulmonary venous hypertension may be free of wheezing and spirometric evidence of airflow obstruction although they complain of dyspnoea. In mitral stenosis, pulmonary venous hypertension causes interstitial fibrosis and haemosiderosis resulting in loss of total lung capacity and changes in J. V. Collins, T. J. H. Clark and D . J. Brown pulmonary compliance (Wood, McLeod, Anthonisen & Macklem, 1971 ). This 'brown induration' of the lungs is usually less marked in diseases causing left ventricular failure probably because pulmonary venous hypertension in these is of shorter duration at the time of presentation with symptoms (Bates, Macklem & Christie, 1971) . Recent studies of the genesis of pulmonary oedema suggest that persistent or recurrent oedema results in changes in the interstitial connective tissues surrounding the smaller non-cartilaginous airways of the lungs (Staub, 1970) .
The closing volume test used in the present study is an indirect measure of regional inequalities of ventilation of the lung and is believed to reflect the behaviour of the small peripheral airways (Dollfuss, Milic-Emili & Bates, 1967) . The two objectives of the present study were:
1. To see if abnormalities of closing volume were present in patients with various left heart diseases in the absence of clinical or conventional spirometric evidence of airflow obstruction.
2, Whether the degree of abnormality of closing volume was related to the severity and duration of symptoms or haemodynamic findings at cardiac catheterization.
Methods

Subjects
Forty healthy subjects of both sexes who had never smoked were studied to provide a control group for comparison for the various tests of pulmonary function. All were free from symptoms of pulmonary disease and denied a history of cough and sputum. Eighty patients with left heart diseases were studied while in hospital for elective haemodynamic assessment or operation. The majority of patients had isolated or mixed defects of the mitral and aortic valves (see Table 1 ). The patients were chosen because they had no history of cough and the majority (i.e. sixty-two patients, 77.5%) had never smoked. All the remaining patients had stopped smoking at least 5 years before the study, sixteen patients (20%) had previously smoked only cigarettes and two had been pipe-smokers. A history was taken from each patient and the severity and duration of dyspnoea was graded by using a standardized questionnaire (Fletcher, 1952) . A clinical examination of the cardiovascular and respiratory systems was made in all healthy subjects and patients and the presence of Measurements of forced vital capacity (FVC) and forced expired volume in 1 s (FEVI) were made in all healthy subjects and patients in the study with a water-canister spirometer (Expirograph type 112, Godart NV). In each subject, three recordings of FEVl and FVC were made at each stage in a study and the largest value for each index was recorded. Total airways resistance and thoracic gas volume were measured in fifteen of the healthy subjects and seventeen cardiac patients with a constant-volume body plethysmograph (DuBois, Botelho, Bedell, Marshall & Comroe, 1956 ). Inspiratory and expiratory How rates were measured with a Fleisch pneumotachograph (model no. 2), linear for flow rates in the range 0-180 l/min. A metronome was used to regulate panting frequency to 1 Hz. For each subject, five readings were made of total airways resistance (Raw) and thoracic gas volume after discarding two preliminary readings.
Closing volume was measured with '"Xe as the marker gas. Xenon concentration at the mouth was recorded by a scintillation detector and photomultiplier fitted with a lead collimator (J and P Engineering Ltd). The signal from the detector was amplified by an amplifier discriminator NM 12 and the counter by a rate meter NM 172 (J and P Engineering Ltd). The signal was then recorded on the Y axis of an XY recorder (Hewlett Packard 7005) with a simultaneous record of expired volume on X axis measured by a potentiometer fitted to a spirometer (P. K. Morgan Ltd, mark 2). Throughout the studies, inspiratory and expiratory flow rates were maintained at less than 0.5 l/s. After suitable practice, three to five traces were recorded for each subject with ls3Xe at each stage of the study, the maximum number of traces recorded for any subject for one study being fifteen. Each trace was recorded with 0.1-0.3 mCi of ls3Xe and the total time for one inhalation-exhalation was approximately 30 s. A total dose of 1-3 mCi of 133Xe was used in each complete subject study; thus the absorbed radiation dose for the lungs was of the order of 14-42 mrad (Clark, Matthews, Silvester & Von Berg, 1967) . ls3Xe was chosen as the marker gas because the quality of the closing volume traces was superior to those obtainable with the nitrogen washout method and allowed more precise determination of closing volume. The purposes and nature of the studies was explained to all healthy subjects and patients and consent was obtained. jects seated erect and then lying supine without inhalation of salbutamol. Cardiac patients. In seventy-two cardiac patients, measurements were made of closing volume whilst seated erect before and after the inhalation of a salbutamol aerosol (840 nmol; 200 fig) as for the healthy subjects. Fifty-six (78 %) patients were nonsmokers; the remainder were ex-cigarette smokers. In twenty of the non-smoking patients, closing volume was measured whilst seated erect and lying supine before the inhalation of salbutamol. Measurements of closing volume, total airways resistance and thoracic gas volume were made in seventeen cardiac patients before and after inhalation of salbutamol (840 nmol; 200 pg) on a separate occasion.
Terminology. Closing volume traces were used only when the junction between phase 3 (alveolar plateau) and phase 4 (closing volume) was easily discernible. Representative examples of closing volume traces are shown in Fig. 4 . Each trace was stored and later measured by two independent observers, one of whom had not been present at the recording. Observer estimates of the size of closing volume were com- pared, replicated traces from ten normal subjects and ten cardiac patients before and after inhalation of a salbutamol aerosol (840 nmol; 200 fig) being used.
Results in the present study were expressed as closing volume (i.e. phase 4) as a percentage of iital capacity.
Results
Reproducibility of phase 4
When the two observers' estimates of closing volume were compared, none of the mean differences between the estimates was significantly different from zero for either cardiac patients or normal subjects. Since there was no significant difference between the two observers for pooled within-subject variance for either normal subjects or cardiac patients before or after salbutamol, overall estimates of within-subject variance were obtained for each group. Again there was no significant difference in overall within-subject variance before or after salbutamol for either group (in every instance PaO.10 for these differences).
Healthy subjects. There were no statistically significant differences between the spirometric measurements in the healthy subjects and predicted values obtained from Cotes (1968) . These are summarized in Table 2 . The effects of inhalation of salbutamol on the spirometric measurements, closing volume and the ratio closing volume/vital capacity are shown in Table 3 and the regression with age of closing volume/vital capacity is shown in Table 4 .
The only significant change in ventilatory capacity in the healthy subjects after salbutamol was an increase in FEVl (P<O.OOl). There were no significant changes in the slope or y-intercept of the regression with age of closing volume/vital capacity after salbutamol. When the effects of change in posture from seated erect to lying supine were examined in the healthy subjects significant reductions in FEVl and FVC (P < 0.001) were observed, as shown in Table 5 . Closing volume was almost identical in the two positions but because of the reduction of FVC in the supine position the ratio closing volumelvital capacity was significantly greater in this position (P<O.O2). The slopes and y-intercepts of the regression with age of closing volume/vital capacity were not significantly different in the two positions (see Table 6 ). For the differences between the slopes P = 0435 and for the y-intercepts P = 0.45. For the fifteen healthy subjects in whom measurements of total airways resistance (Raw) and specific airways conductance (SG.,) were made, the group mean values ( +SD) before salbutamol were R., = 0~105rt0.041 kPa I-ls (1.0550.41 cmHIO ]-Is) and SG., = 3@If0.84 s -l k P a -' (0.309rt: 0.084 s -'cmH,O -l). These measurements were not repeated after salbutamol in this group. Cardiac patients. Group mean values for all conventional spirometric measurements in the cardiac patients were significantly different from those recorded in the healthy subjects and from the predicted values obtained from Cotes (1968): in all instances P<O.OOl for the differences. When the cardiac patients were divided into two groups, nonsmokers and ex-smokers, the differences for the group mean values of each group from the healthy subjects and the predicted values were of the same order of significance except for group mean FVC in the ex-smokers, where for the difference from the group mean in healthy subjects P<O.Ol. There were no significant differences between non-smokers and Table 2 . Data for FEVI, FVC, closing volume and the ratio closing volume/vital capacity for the mixed group of seventy-two cardiac patients are shown in Table 7 . There were significant changes in all measurements after the inhalation of salbutamol. The values for the ratio closing volume/vital capacity for the various groups of cardiac patients are given in Table 4 . When the mixed group of cardiac patients was compared with the group of healthy subjects there were significant differences in the y-intercept of the regression of closing volume/ vital capacity both before and after salbutamol (P -= 0.001 and P < 0.01 respectively). The differences in the slope of the regression before and after salbutamol between the two groups were not significant (P = 0.49 and 0.19 respectively) but there were highly significant differences between the cardiac patients and the healthy subjects for the correlation coefficients and 95 % confidence intervals of the regression equations both before and after salbutamol (for the difference in every case P<O.OOl).
When the cardiac patients were divided into two groups, non-smokers and ex-smokers, there were no significant differences between the group mean values for FEVl or FVC. Similarly, when the equations for the regression with age of the ratio closing volume/ vital capacity in these two groups were compared there were no significant differences in the slopes, y-intercepts, correlation coefficients or 95 % confidence intervals of the regression. However, there were highly significant differences in the correlation coefficients and 95% confidence intervals of the regression in each of these sub-groups compared with the group of healthy subjects (P<O.OOl in every case), but there were no significant differences in the
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slopes of the regressions. The y-intercept in the nonsmokers was significantly different from that of the healthy subjects (P <0.05).
When the effects on ventilatory function of change of posture from seated erect to lying supine were examined in twenty cardiac patients significant reductions were observed in FEV, and EVC (P < 0.001). The ratio closing volume/vital capacity was not significantly different with the change of posture (P = 0.47). These results are summarized in Table 8 . As with the group of healthy subjects, when the equations for the regression with age of closing volume/vital capacity in the two positions were compared there were no significant differences in the slopes or y-intercepts (see Table 6 ). The slope of the regression and y-intercept of the regression with age of closing volume/vital capacity was not significantly different in either position in the cardiac patients compared with the healthy subjects.
More detailed studies of the effects of salbutamol on measurements of lung volumes and total airways resistance were made in a body plethysmograph in seventeen cardiac patients (see Table 9 ). There was no significant change in total lung capacity or functional residual capacity after salbutamol but there were significant increases in FEV1, FVC and specific airway conductance. These were accompanied by reductions in closing volume, the ratio closing volume/vital capacity and total airways resistance.
To examine the effects on ventilatory function of isolated aortic stenosis or mitral stenosis, two groups of patients were selected on the basis of clinical examination and in all patients the clinical diagnosis was confirmed at cardiac catheterization or operation. There were nine patients with aortic stenosis and fourteen patients with mitral stenosis. There were no significant differences between the groups with respect to age or the length of time for which symptoms of heart disease had been present. Before inhalation of salbutamol there was no significant difference in ventilatory function between the two groups; for the differences in group mean values for FEV,, FVC, closing volume and the ratio closing volumelvital capacity P = 0.18, 0.16, 0.15 and 0.88 respectively. Table 10 shows that small increases in FEV, and FVC were observed in both groups after salbutamol and there were significant reductions in closing volume and closing volume/vital capacity (PGO.01). However, there were no significant differences between the groups in the degree of changes after salbutamol (P 3033).
Relationship of clinical features of heart disease to closing volumeloital capacity
The relationship of the ratio closing volume/vital capacity and various estimates of the severity of heart disease were examined, including breathlessness at the time of the study, duration of symptoms of heart disease, time since first recorded episode of heart failure, left ventricular end-diastolic pressure and left atrial pressure (PCV wedge pressure). In an attempt to compensate for age-related increases in closing volume/vital capacity common to healthy subjects and cardiac patients a 'predicted' closing volume/vital capacity for each cardiac patient was derived from the regression with age of closing closing volume/vital capacity and age-corrected 'excess' closing volume/vital capacity are shown in Table 1 1 . To summarize these results, the severity of breathlessness at the time of the study appealed to be dominated by age-related effects and there was no significant correlation between the degree of breathlessness and 'excess' closing volume/vital capacity (P = 0.44). Both measured and 'excess' closing volumelvital capacity were significantly correlated with the duration of symptoms of heart disease (for both, P < 0.05) and the time since the first episode of heart failure (for both, P < 0.01). However, haemodynamic measurements were not significantly correlated with either measured or 'excess' closing volume vital capacity.
Discussion
The reproducibility of measurements of closing volume and the regression with age of closing volume/vital capacity in the healthy subjects were similar to previous reports (Leblanc, Ruff & MilicEmili, 1970; McCarthy, Spencer, Greene & MilicEmili, 1972; Buist &Ross, 1973) . The reproducibility of measurements of closing volume in the cardiac patients was of the same order as that in the healthy subjects.
For the cardiac patients, there were highly significant differences in both closing volume and closing volume/vital capacity compared with healthy subjects both before and after salbutamol. Although this increase above the values in healthy subjects was partially reversible by salbutamol in the cardiac patients no such change was observed in the healthy subjects. The more extensive studies conducted in a group of seventeen cardiac patients showed that these increases in closing volume and closing volume/ vital capacity before salbutamol were associated with raised total airways resistance and diminished specific airways conductance. The reduction in closing volume and closing volumelvital capacity which followed the inhalation of salbutamol in this group was accompanied by a reduction in total airways resistance to values not significantly different from the range for healthy subjects but specific airways conductance remained significantly reduced, although it showed some improvement. Another effect of salbutamol in these patients was to change the relationship of expiratory reserve volume minus closing volume from a group mean value of -0.03 1 1 before salbutamol to +0.581 1 after salbutamol. It is possible that such changes might be associated with reduction in the size of non-ventilated areas of the lungs and could lead to a reduction in the alveolararterial oxygen tension difference and an increase in arterial oxygen tension. On a subsequent occasion, several of the patients in this sub-group who had shown marked changes with salbutamol were restudied before and after inhalation of an atropine aerosol. This was administered as an aqueous solution of atropine methonitrate (5.5 mmol/l; 2 g/l) inhaled for 2 min from a Wright's nebulizer powered by compressed air at a flow rate of 8 I/min. Several of these patients showed marked reduction in closing volume after atropine without concomitant changes in vital capacity. As a result, the ratio closing volume/vital capacity was significantly reduced. When they inhaled salbutamol (840 nmol; 200 pg) 40 min after the atropine no further change occurred in closing volume or vital capacity. These changes are illustrated for four patients in Fig. 3 . The implications of these changes after atropine are uncertain and as the particle sizes of the aerosols generated by metered salbutamol aerosols and Wright's nebulizers may well be different it is possible that the two drugs were acting at different sites in the bronchial tree. However, it is interesting that changes effected by atropine were not further enhanced by salbutamol. When atropine was administered to twenty-four healthy subjects, no significant changes were observed in closing volume or vital capacity.
Change of posture from seated erect to lying supine in the twenty cardiac patients did not change the ratio closing volumelvital capacity significantly, which contrasts with the findings in the healthy subjects. Increased airway closure with recumbency causing mismatching of ventilation and perfusion has been suggested as a possible mechanism leading to the progressive reduction in arterial oxygen tension with age which has been observed in healthy subjects (Holland, Milic-Emili, Macklem & Bates, 1968; Mellemgaard, 1966) . It seemed possible that increased airway closure with recumbency might be partly responsible for the production of orthopnoea. All the twenty cardiac patients who were studied supine had experienced orthopnoea, but our results suggest that at least at the time of the studies this group would not have increased airway closure during tidal breathing in the supine position.
Relationship of closing volume to heart diseases
Because left atrial pressure will usually have been raised for longer in patients with mitral stenosis compared with patients with aortic stenosis the attendant effects upon the lungs may be greater in mitral stenosis. However, in the present study there were no significant differences before inhalation of salbutamol between the patients with aortic stenosis and those with mitral stenosis, and the changes which followed the inhalation of this drug did not differ significantly between the two groups. The calculation of an 'excess' closing volume/vital capacity was undertaken in the hope that any increase in closing volume/vital capacity due to heart disease might thereby be separated from age-dependent effects. Certainly, 'excess' closing volume/vital capacity was shown not to be significantly correlated with age. However, although measured closing volumelvital capacity was significantly correlated with severity of breathlessness and length of symptom history, 'excess' closing volume/vital capacity was only significantly correlated with the time since the first episode of heart failure. Moreover, there was no significant correlation between left ventricular end-diastolic pressure or pulmonary vein wedge pressure and either measured or 'excess' closing volume/vital capacity .
Closing volume and fluid overload
I n an earlier study of the effects of acute blood volume expansion by intravenous infusion of physiological sodium chloride solution in healthy subjects (Collins, Cochrane, Davis, Benatar & Clark, 1973) small reductions in static and expired lung volumes and significant increases in closing volume/ vital capacity were recorded after completion of the infusions. These changes in pulmonary function bore some resemblance to the abnormalities observed in patients with heart diseases in the present study and may suggest that early pulmonary congestion or oedema may cause an increase in dependent airway closure with increase in closing volume. A study of patients with chronic uraemia provides some support for this hypothesis (Stanescu, Veriter, Plaen, Frans, Strihou & Brasseur, 1974) . Closing volume was increased above normal values in.the patients studied by Stanescu et al. (1 974) and fluid removal by haemodialysis was accompanied by significant reduction in closing volume. It is possible that measurement of closing volume may be useful for detecting sub-clinical pulmonary congestion or oedema and other causes of increased pulmonary extravascular fluid volume.
